Evidence map›Paper›PMID 7567993›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1995

Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750.

R C Inhorn, N Carlesso, M Durstin, D A Frank, J D Griffin

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

R C InhornDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
N Carlesso
M Durstin
D A Frank
J D Griffin
Dana-Farber Cancer Institute · US

Funding

SURFACE ANTIGENS OF MYELOID PROGENITOR CELLSR01CA036167 · NCI · DANA-FARBER CANCER INSTITUTE · PI GRIFFIN, JAMES DOUGLAS · 1985 to 2007
$1.8M
REGULATION OF MYELOPOIESISR37CA036167 · NCI · DANA-FARBER CANCER INSTITUTE · PI GRIFFIN, JAMES D · 1995 to 2002
$863k
NCI NIH HHS CA 34185NCI NIH HHS CA 36167
6 · The paper itself

Abstract

The granulocyte/macrophage colony-stimulating factor (GM-CSF) receptor (GMR) is a heterodimeric receptor expressed by myeloid lineage cells. In this study we have investigated domains of the GMR beta-chain (GMR beta) involved in maintaining cellular viability. Using a series of nested GMR beta deletion mutants, we demonstrate that there are at least two domains of GMR beta that contribute to viability signals. Deletion of amino acid residues 626-763 causes a viability defect that can be rescued with fetal calf serum (FCS). Deletion of residues 518-626, in contrast, causes a further decrement in viability that can be only partially compensated by the addition of FCS. GMR beta truncated proximal to amino acid 517 will not support long-term growth under any conditions. Site-directed mutagenesis of tyrosine-750 (Y750), which is contained within the distal viability domain, to phenylalanine eliminates all demonstrable tyrosine phosphorylation of GMR beta. Cell lines transfected with mutant GMR beta (Y750-->F) have a viability disadvantage when compared to cell lines containing wild-type GMR that is partially rescued by the addition of FCS. We studied signal transduction in mutant cell lines in an effort to identify pathways that might participate in the viability signal. Although tyrosine phosphorylation of JAK2, SHPTP2, and Vav is intact in Y750-->F mutant cell lines, Shc tyrosine phosphorylation is reduced. This suggests a potential role for Y750 and potentially Shc in a GM-CSF-induced signaling pathway that helps maintain cellular viability.

Indexed as

Cell Cycle ProteinsAnimalsB-LymphocytesCell LineCell SurvivalDNA Mutational AnalysisEnzyme ActivationIntracellular Signaling Peptides and ProteinsJanus Kinase 2MiceMutagenesis, Site-DirectedPhosphorylationProtein ConformationProtein-Tyrosine KinasesProtein Tyrosine Phosphatase, Non-Receptor Type 11Protein Tyrosine Phosphatase, Non-Receptor Type 6Cell Cycle ProteinsIntracellular Signaling Peptides and ProteinsJak2 protein, mouseJanus Kinase 2Protein-Tyrosine KinasesProtein Tyrosine Phosphatase, Non-Receptor Type 11Protein Tyrosine Phosphatase, Non-Receptor Type 6Protein Tyrosine PhosphatasesProto-Oncogene ProteinsProto-Oncogene Proteins c-vavProto-Oncogene Proteins pp60(c-src)Ptpn11 protein, mousePtpn6 protein, mouseReceptors, Granulocyte-Macrophage Colony-Stimulating FactorRecombinant ProteinsTyrosineVav1 protein, mouse

Identifiers

PMID7567993
PMCPMC41027
OpenAlexW2003041430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.